A detailed history of Marshall Wace, LLP transactions in Galapagos Nv stock. As of the latest transaction made, Marshall Wace, LLP holds 12,715 shares of GLPG stock, worth $362,377. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,715
Holding current value
$362,377
% of portfolio
0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$24.78 - $32.48 $315,077 - $412,983
12,715 New
12,715 $315,000
Q2 2023

Aug 14, 2023

BUY
$37.4 - $44.52 $1.15 Million - $1.37 Million
30,776 Added 239.71%
43,615 $1.77 Million
Q1 2023

May 15, 2023

BUY
$36.5 - $48.0 $468,623 - $616,272
12,839 New
12,839 $496,000
Q3 2022

Nov 14, 2022

BUY
$42.27 - $57.6 $724,888 - $987,782
17,149 New
17,149 $732,000
Q1 2022

May 16, 2022

SELL
$51.32 - $68.5 $319,467 - $426,412
-6,225 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$47.03 - $57.12 $292,761 - $355,572
6,225 New
6,225 $344,000
Q3 2020

Nov 16, 2020

SELL
$122.47 - $213.56 $584,426 - $1.02 Million
-4,772 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$185.52 - $231.25 $885,301 - $1.1 Million
4,772 New
4,772 $941,000
Q4 2019

Feb 14, 2020

SELL
$146.12 - $215.82 $253,079 - $373,800
-1,732 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$130.44 - $187.64 $225,922 - $324,992
1,732 New
1,732 $264,000
Q2 2019

Aug 14, 2019

SELL
$111.45 - $128.93 $2.65 Million - $3.06 Million
-23,767 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$89.61 - $117.78 $6.27 Million - $8.24 Million
-69,991 Reduced 74.65%
23,767 $2.8 Million
Q4 2018

Feb 14, 2019

SELL
$87.81 - $110.65 $3.73 Million - $4.7 Million
-42,494 Reduced 31.19%
93,758 $8.6 Million
Q3 2018

Nov 14, 2018

BUY
$90.63 - $120.22 $12.3 Million - $16.4 Million
136,252 New
136,252 $15.3 Million
Q2 2018

Aug 14, 2018

SELL
$88.4 - $105.34 $3.77 Million - $4.49 Million
-42,649 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$94.51 - $120.23 $4.03 Million - $5.13 Million
42,649 New
42,649 $4.26 Million

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.88B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.